Internship

Financial Planning & Analysis Summer Intern

Posted on 12/20/2024

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$25 - $31Hourly

No H1B Sponsorship

San Carlos, CA, USA

Must work at the Redwood City office for the duration of the internship, no relocation available.

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Financial analysis
Data Analysis
Requirements
  • Strong verbal and communication skills
  • Highly motivated with a desire to learn
  • Must be able to complete at least 10 consecutive weeks between June and August and it is a full-time internship (40 hours per week)
  • Must be able to work at our Redwood City office for the duration of the internship, no relocation available
  • MBA / MBA candidate
  • Finance, economics, or related business major
  • Applicants must be currently authorized to work in the United States on a full-time basis.
Responsibilities
  • Assist with pre-budget financial modeling
  • Design and scope the Budget process
  • Support functional area forecasts through data analytics and key performance metrics
  • Support monthly/quarterly financial analysis reporting
  • Deliver a department presentation at the end of the program
  • Participate as a member of the 2025 intern team group project that includes a company-wide presentation

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is the first FDA-approved treatment for Cushing's syndrome, a condition caused by excessive cortisol. The company has discovered over 1,000 selective cortisol modulators and aims to expand its offerings with new treatments in development. Unlike many competitors, Corcept emphasizes both research and patient education, providing resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions. The goal of Corcept is to lead in cortisol modulation therapies and enhance the quality of life for patients suffering from disorders related to cortisol imbalance.

Company Stage

IPO

Total Funding

$39.7M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

23%

1 year growth

31%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Growing interest in cortisol therapies boosts demand for Corcept's products.
  • Advancements in AI-driven drug discovery could accelerate Corcept's R&D processes.
  • Telemedicine expansion increases access to treatments like Korlym, broadening market reach.

What critics are saying

  • Teva's antitrust lawsuit could lead to legal expenses and market share loss.
  • Heavy reliance on Korlym makes Corcept vulnerable to market or regulatory changes.
  • Strategic shift to oncology may divert resources from core cortisol modulation focus.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few direct competitors.
  • Korlym is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome.
  • Corcept has discovered over 1,000 selective cortisol modulators, showcasing strong R&D capabilities.

Help us improve and share your feedback! Did you find this helpful?